Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07612293 · ClinicalTrials.gov registry record · NA
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
A NA study, sponsored by Jonsson Comprehensive Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07612293: Clinical Trial NA study, sponsored by Jonsson Comprehensive Cancer Center.
NCT07612293 is a NA study that has not yet begun recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07612293, a NA study, has not yet begun recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and/or more effective way to treat sporadic MTC.
Primary Outcome
Will calculate the proportion of patients who achieve biochemical remission at 3 months (normal calcitonin and carcinoembryonic antigen \[CEA\]). Exact 95% confidence intervals will be provided. Exploratory subgroup analyses (e.g., stratified by baseline calcitonin level, tumor size, or nodal status) may be conducted to generate hypotheses but will not be powered for formal inference.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Neck Dissection
- PROCEDURE FDG-Positron Emission Tomography and Computed Tomography Scan
- PROCEDURE Ga-68 PET/CT Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-09-02 |
| Est. Completion | 2032-04-21 |
| Phase | NA |
What is known before NCT07612293 opens enrollment
NCT07612293 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT07612293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07612293 about?
NCT07612293 is a clinical study titled "STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection". This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are ...
What is the current status of trial NCT07612293?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-09-02. Estimated completion is 2032-04-21.
What interventions are being tested in trial NCT07612293?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Neck Dissection (PROCEDURE), FDG-Positron Emission Tomography and Computed Tomography Scan (PROCEDURE), Ga-68 PET/CT Scan (PROCEDURE).
Who is sponsoring clinical trial NCT07612293?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07612293's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI